BTN3A1 and neoplasm: For example, the use of an agonistic BTN3A1 antibody, which binds to BTN3A1+ cancer cells, triggers phosphoantigen-like Vγ9Vδ2 T activation and tumor recognition82,633 A phase I/IIA clinical trial of this strategy is currently underway (NCT04243499).